Legislator Case Law & Legislation
812.21 HMGLPTHLATER CH AI generated

Art. 59 Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (TPA) - Mandatory notification, notification system and the right to notify

TPA; Chapter 4 Common Provisions on Medicinal Products and Medical Devices
Open official source Full Act (141 Articles) Machine-readable Markdown (.md)

Legislator summary

AI generated

Any person manufacturing or distributing ready-to-use therapeutic products must put in place a system of notification. He must notify the Agency of any adverse event or reaction which: a. is or may be attributable to the therapeutic product itself, its use or to incorrect labelling or instructions; b. may endanger or damage the health of the consumer, of the patient, of a third party or of the treated animals. Any person manufacturing or distributing therapeutic products must furthermore notify the Agency of any quality defects and any further findings and assessments which could influence the basis of evaluation. Any person who professionally dispenses therapeutic products or administers them to humans or animals or who is entitled to do so as medical personnel must notify the Agency of any serious or previously unknown adverse effects and incidents, observations of other serious or previously unknown facts or quality defects that are of significance for drug safety. {note: Amended by No I of the FA of 18 March 2016, in force since 1 Jan. 2019 ( AS 2017 2745, 2018 3575; BBl 2013 1).} 3 bis Any person who manufactures or places on the market therapeutic products must report to the Agency any suspicion of illegal trading in therapeutic products by third parties that come to its knowledge in connection with its activities, its products or their components. {note: Inserted by Annex No 2 of the FD of 29 Sept. 2017 (Medicrime Convention), in force since 1 Jan. 2019 ( AS 2018 4771; BBl 2017 3135).} Consumers, patients and their organisations as well as interested third parties, may notify the Agency for adverse events and reactions with therapeutic products. The notifications referred to in paragraphs 1–3 shall be made in accordance with the recognised rules of good vigilance practice. {note: Inserted by No I of the FA of 18 March 2016, in force since 1 Jan. 2019 ( AS 2017 2745, 2018 3575; BBl 2013 1).} The Federal Council shall define the recognised rules of good vigilance practice. It shall take into account internationally recognised guidelines and standards. {note: Inserted by No I of the FA of 18 March 2016, in force since 1 Jan. 2019 ( AS 2017 2745, 2018 3575; BBl 2013 1).} Employees of persons and organisations who manufacture, distribute, prescribe or dispense therapeutic products are entitled to notify the competent authorities of observations that indicate a violation of the provisions of this Act. {note: Inserted by No I of the FA of 18 March 2016, in force since 1 Jan. 2019 ( AS 2017 2745, 2018 3575; BBl 2013 1).}

Art. 59 TPA · Mandatory notification, notification system and the right to notify

Anyone who manufactures therapeutic products or distributes ready-to-use therapeutic products must ensure that a reporting system is in place. They must report to the Institute adverse effects and incidents that: a. are attributable, or could be attributable, to the therapeutic product itself, its use, or improper labeling or instructions for use; b. could endanger or impair the health of consumers, patients, third parties, and treated animals.

Anyone who manufactures or distributes therapeutic products must also report to the Institute quality defects as well as other findings and assessments that may influence the basis for evaluation.

Anyone who dispenses therapeutic products professionally, applies them to humans or animals, or is authorized to do so as a medical professional must report to the Institute serious or previously unknown adverse effects and incidents, observations of other serious or previously unknown facts, as well as quality defects that are significant for the safety of therapeutic products.

Anyone who manufactures or places therapeutic products on the market must report to the Institute any suspicion of illegal trade in therapeutic products by third parties that they discover in connection with their activity, one of their products, or its components.

Consumers, patients, their organizations, and interested third parties may report adverse effects of therapeutic products and incidents to the Institute.

Reports pursuant to paragraphs 1–3 must be submitted in accordance with the recognized rules of Good Vigilance Practice.

The Federal Council shall define the recognized rules of Good Vigilance Practice in more detail. In doing so, it shall take into account internationally recognized guidelines and standards.

Employees of persons and organizations that manufacture, distribute, prescribe, or dispense therapeutic products are entitled to report observations to the competent authorities that suggest a violation of the provisions of this Act.

← Art. 58 TPA Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (TPA) - Purpose Art. 60 TPA →

Need to analyze how this provision applies to your matter?

Cross-reference this statute against case law, commentaries, and related legislative provisions inside Legislator AI.

Open in Legislator →

Court Decisions Applying This Provision (5)

C-3076/2020 (Art. 59 Abs. 2 HMG)
Pharmaceutical Company v. Regulatory Agency: Muscle Relaxant Indications Dispute
This provision was initially cited by Swissmedic as the basis for finding a violation of the reporting obligation by A._______ SA, but was ultimately annulled by the court. However, it was part of the original administrative order which the court is reviewing.
A-3334/2019 (Art. 59 al. 1 LPTh)
Access to Prosthetic Device Incident Reports, Including User and Manufacturer Data
Obligation of manufacturers to report adverse events or incidents related to therapeutic products.
A-3334/2019 (Art. 59 al. 3 LPTh)
Access to Prosthetic Device Incident Reports, Including User and Manufacturer Data
Obligation of users (healthcare professionals) to report serious incidents to Swissmedic.
C-5649/2015 (Art. 59 Abs. 2 HMG)
Drug Manufacturer Fails to Prove Efficacy for Muscle Spasms, Partially Wins Reporting Case
Used to establish the obligation to report further findings and evaluations that could influence the basis of assessment, which was found to be misapplied in the original decision.
JAAC 67.59 (Art. 59 Abs. 3 HMG)
Hip Prosthesis Case: Anonymized Data Disclosure Upheld
Cited to establish the obligation of healthcare professionals to report incidents, which underpins the need for confidentiality in the market surveillance system.